These observations suggest that activation of CLEC2 and CLEC5A/TLR2 in platelets and leukocytes by DV and IAV contributes significantly to disease severity, and simultaneous blockade of CLEC5A and TLR2 has a great potential to treat DV, IAV, and other viral infections in the future. The gene discussed is CLEC1B; the disease is viral infectious disease.